Echocardiographic Meas. of LA Function & Size With Dementia
For a study, researchers sought to look at the relationship between (Left Atrial) LA function and...
Read More
Oncology
#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer
Click to read this study in JAMA Oncology.
Read More
Carotuximab addition to pazopanib does not improve survival in advanced angiosarcoma patients
1. Carotuximab in tandem with pazopanib did not show improvement in progression-free survival or...
Read More
Adherence to pre-treatment imaging guidelines for staging in rectal cancer is increasing, but a gap still remains
1. Adherence to the guidelines increased from 38% to 56% between Fall 2016 and 2019; and from 37%...
Read More
Induction chemotherapy with paclitaxel, cisplatin and capecitabine showed promising clinical and safety response to treat advanced nasopharyngeal carcinoma
1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and...
Read More
Obesity may be associated with better response to immune checkpoint blockade therapy
1. In this study, patients who were obese or overweight had better survival compared to normal...
Read More
Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of...
Read More
Darolutamide with chemotherapy and androgen-deprivation therapy improves overall survival in metastatic hormone-sensitive prostate cancer
1. Overall survival was significantly longer in patients taking darolutamide in tandem with...
Read More
Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared...
Read More
Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer
1. Patients with hormone-sensitive prostate cancer receiving darolutamide, an androgen-receptor...
Read More
Religious attendance may be correlated with cancer screening utilization
1. This study found there was a positive association between religious attendance and cancer...
Read More
Examining Age Disparity in Clinical Trial Understanding
“Older adults with cancer are underrepresented in clinical trials, despite comprising the majority...
Read More
Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma
1. Treatment with pembrolizumab yielded a best overall response rate of 71%. 2. Adverse events...
Read More
Ribociclib in addition to letrozole increases overall survival compared to letrozole alone
1. Overall survival was longer in the group receiving ribociclib with letrozole as compared with...
Read More
Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma
1. The median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in...
Read More
Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to...
Read More
Breast cancer overdiagnosis rates not as high as estimated previously
1. About 1 in 7 cases of screen-detected cancer is overdiagnosed in the US population. 2. The rate...
Read More
Postoperative treatment without radioiodine has noninferior outcomes following thyroidectomy
1. Patients with low-risk thyroid cancer undergoing thyroidectomy, who did not receive radioiodine...
Read More
Non-alcoholic fatty liver disease-related hepatocellular carcinoma (HCC) differ clinically compared to HCC due to other causes
1. Patients with NAFLD-related HCC have longer disease-free survival compared to those with HCC...
Read More
Hepatocellular Carcinoma: The Viral Hepatitis Pathways
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and incidence...
Read More